Abstract
Purpose: RECIST have limitations when applied to potentially curable locally advanced squamous cell carcinoma of the head and neck (SCCHN). [18F]fluorodeoxyglucose-positron emission tomography (PET) scan may be useful in assessing treatment response and predicting patient outcome. Patients and methods: We studied patients with previously untreated stages III-IVb SCCHN treated with primary concurrent chemoradiotherapy on five prospective clinical trials. Response was assessed by clinical exam, computed tomography (CT), and PET portions of combined PET-CT scan ∼8 weeks after completion of chemoradiotherapy.Results: Fifty-three patients were analyzed. Complete response (CR) was demonstrated in 42 patients (79%) by clinical exam, 15 (28%) by CT, and 27 (51%) by PET. CR as assessed by PET, but not as assessed by clinical exam or CT using RECIST, correlated significantly with progression-free status (PFS) (P < 0.0001). The 2-year PFS for patients with CR and without CR by PET was 93% and 48%, respectively (P = 0.0002).Conclusions: A negative PET scan on combined PET-CT after chemoradiotherapy is a powerful predictor of outcome in patients receiving curative chemoradiotherapy for SCCHN. PET-CT is indicated for response evaluation in this setting to improve the accuracy of post-treatment assessment by CT.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2278-2283 |
| Number of pages | 6 |
| Journal | Annals of Oncology |
| Volume | 21 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2010 |
| Externally published | Yes |
Fingerprint
Keywords
- Chemoradiotherapy
- Head and neck cancer
- Objective response
- PET-CT
- RECIST
ASJC Scopus subject areas
- Oncology
- Hematology
Cite this
Response assessment by combined PET-CT scan versus ct scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. / Passero, V. A.; Branstetter, B. F.; Shuai, Y.; Heron, D. E.; Gibson, M. K.; Lai, S. Y.; Kim, S. W.; Grandis, J. R.; Ferris, R. L.; Johnson, J. T.; Argiris, A.
In: Annals of Oncology, Vol. 21, No. 11, 11.2010, p. 2278-2283.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Response assessment by combined PET-CT scan versus ct scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy
AU - Passero, V. A.
AU - Branstetter, B. F.
AU - Shuai, Y.
AU - Heron, D. E.
AU - Gibson, M. K.
AU - Lai, S. Y.
AU - Kim, S. W.
AU - Grandis, J. R.
AU - Ferris, R. L.
AU - Johnson, J. T.
AU - Argiris, A.
PY - 2010/11
Y1 - 2010/11
N2 - Purpose: RECIST have limitations when applied to potentially curable locally advanced squamous cell carcinoma of the head and neck (SCCHN). [18F]fluorodeoxyglucose-positron emission tomography (PET) scan may be useful in assessing treatment response and predicting patient outcome. Patients and methods: We studied patients with previously untreated stages III-IVb SCCHN treated with primary concurrent chemoradiotherapy on five prospective clinical trials. Response was assessed by clinical exam, computed tomography (CT), and PET portions of combined PET-CT scan ∼8 weeks after completion of chemoradiotherapy.Results: Fifty-three patients were analyzed. Complete response (CR) was demonstrated in 42 patients (79%) by clinical exam, 15 (28%) by CT, and 27 (51%) by PET. CR as assessed by PET, but not as assessed by clinical exam or CT using RECIST, correlated significantly with progression-free status (PFS) (P < 0.0001). The 2-year PFS for patients with CR and without CR by PET was 93% and 48%, respectively (P = 0.0002).Conclusions: A negative PET scan on combined PET-CT after chemoradiotherapy is a powerful predictor of outcome in patients receiving curative chemoradiotherapy for SCCHN. PET-CT is indicated for response evaluation in this setting to improve the accuracy of post-treatment assessment by CT.
AB - Purpose: RECIST have limitations when applied to potentially curable locally advanced squamous cell carcinoma of the head and neck (SCCHN). [18F]fluorodeoxyglucose-positron emission tomography (PET) scan may be useful in assessing treatment response and predicting patient outcome. Patients and methods: We studied patients with previously untreated stages III-IVb SCCHN treated with primary concurrent chemoradiotherapy on five prospective clinical trials. Response was assessed by clinical exam, computed tomography (CT), and PET portions of combined PET-CT scan ∼8 weeks after completion of chemoradiotherapy.Results: Fifty-three patients were analyzed. Complete response (CR) was demonstrated in 42 patients (79%) by clinical exam, 15 (28%) by CT, and 27 (51%) by PET. CR as assessed by PET, but not as assessed by clinical exam or CT using RECIST, correlated significantly with progression-free status (PFS) (P < 0.0001). The 2-year PFS for patients with CR and without CR by PET was 93% and 48%, respectively (P = 0.0002).Conclusions: A negative PET scan on combined PET-CT after chemoradiotherapy is a powerful predictor of outcome in patients receiving curative chemoradiotherapy for SCCHN. PET-CT is indicated for response evaluation in this setting to improve the accuracy of post-treatment assessment by CT.
KW - Chemoradiotherapy
KW - Head and neck cancer
KW - Objective response
KW - PET-CT
KW - RECIST
UR - http://www.scopus.com/inward/record.url?scp=77958481883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958481883&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdq226
DO - 10.1093/annonc/mdq226
M3 - Article
C2 - 20430907
AN - SCOPUS:77958481883
VL - 21
SP - 2278
EP - 2283
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 11
ER -